Ergomed PLC
LSE:ERGO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Ergomed PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | UK |
Market Cap | 683.5m GBP |
Net Margin |
10%
|
Country | US |
Market Cap | 1.3T USD |
Net Margin |
9%
|
Country | US |
Market Cap | 196.3B USD |
Net Margin |
14%
|
Country | US |
Market Cap | 170.3B USD |
Net Margin |
18%
|
Country | KR |
Market Cap | 66.5T KRW |
Net Margin |
24%
|
Country | CH |
Market Cap | 37.6B CHF |
Net Margin |
9%
|
Country | US |
Market Cap | 38.5B USD |
Net Margin |
22%
|
Country | US |
Market Cap | 36.7B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 26.4B USD |
Net Margin |
21%
|
Country | US |
Market Cap | 23B USD |
Net Margin |
17%
|
Country | US |
Market Cap | 22.3B USD |
Net Margin |
-36%
|
Ergomed PLC
Glance View
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Ergomed PLC's most recent financial statements, the company has Net Margin of 9.9%.